5-(羟基甲基)噻吩-2-甲腈 | 172349-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-(羟基甲基)噻吩-2-甲腈
• 英文名称: 5-(hydroxymethyl)thiophene-2-carbonitrile
• 英文别名: 5-Hydroxymethylthiophene-2-carbonitrile；2-cyano-5-(hydroxymethyl)thiophene
• CAS: 172349-09-6
• 化学式: C₆H₅NOS
• 分子量: 139.178
• InChiKey: CORJYXNQPRQFPT-UHFFFAOYSA-N

物化性质

• 沸点：
  293.7±25.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(羟基甲基)噻吩-2-甲腈 在 N-甲基吗啉 、 四溴化碳 、 sodium hydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 D-diphenylalanyl-L-prolyl-[(5-cyano-2-thienyl)methyl]amide
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8
• 作为产物：
  描述：

  5-溴噻吩-2-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-(羟基甲基)噻吩-2-甲腈
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8

文献信息

• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US05914319A1

  公开（公告）日：1999-06-22

  This invention relates to thrombin inhibiting compounds having the Formula I X--Y--NH--(CH.sub.2).sub.r --G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

  这项发明涉及具有Formula I X--Y--NH--(CH.sub.2).sub.r --G I的抑制凝血酶化合物，其中X、Y、r和G的值在描述中有定义，以及含有这些化合物的药物配方和它们作为凝血酶抑制剂、凝血抑制剂和血栓性疾病药物的使用方法。
• Direct Regioselective Alkylation of Non-Basic Heterocycles with Alcohols and Cyclic Ethers through a Dehydrogenative Cross-Coupling Reaction under Metal-Free Conditions
  作者：Ebrahim Kianmehr、Maryam Fardpour、Khalid Mohammed Khan

  DOI：10.1002/ejoc.201700030

  日期：2017.5.10

  A metal-free, simple, and highly efficient method for the direct alkylation of non-basic heterocycles and basic ones with various alcohols and cyclic ethers has been developed based on an oxidative C–H activation process. The corresponding products were generated through a dehydrogenative C–C cross-coupling reaction in the presence of di-tert-butyl peroxide in good to high yields.

  基于氧化CH活化过程，开发了一种无金属的，简单而高效的方法，可以将非碱性杂环和碱性杂环与各种醇和环状醚直接烷基化。在过氧化二叔丁基存在下，通过脱氢CC交叉偶联反应生成了相应的产物，收率很高。
• [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES À MÉDIATION PAR COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2022066774A1

  公开（公告）日：2022-03-31

  This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.

  这份披露提供了用于治疗医学障碍的药物化合物，例如补体介导的障碍，包括补体C1介导的障碍。
• Benzisoxazole Compound
  申请人：Sasaki Atsushi

  公开号：US20090318690A1

  公开（公告）日：2009-12-24

  Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: —(CH 2 )m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: —(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

  本发明涉及一种由通式（I）表示的化合物或其盐：其中R1、R2和R3中的任意一个表示公式表示的基团：—（CH2）m-NR11R12（其中m为1或2；R11和R12独立地表示氢原子或C1-6烷基或可能与R11和R12结合的氮原子一起形成4-或5-成员环状基团）；剩余的两个或R1、R2和R3独立地表示公式表示的基团：—（O）n-R21（其中n为0或1；R21表示氢原子、C1-6烷基、C2-6烯基、C2-6炔基等）；R4表示可能具有取代基的C1-6烷基。
• Peptide derivatives as antithrombotic agents
  申请人：AstraZeneca AB

  公开号：EP1361212A1

  公开（公告）日：2003-11-12

  This invention relates to thrombin inhibiting compounds haveing the Formula I         X-Y-NH-(CH2)r-G where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

  本发明涉及具有式 I 的凝血酶抑制化合物 X-Y-NH-(CH2)r-G 其中 X、Y、r 和 G 的值在说明中定义，本发明还涉及含有这些化合物的药物制剂以及将其用作凝血酶抑制剂、凝血抑制剂和血栓栓塞性疾病药物的方法。